8-K filed Aug 10, 2026 at 16:12 ET
Nkarta reported Q2 2026 net loss of $0.54 per share, significantly missing the consensus estimate of -$0.36 per share. The net loss widened to $40.4 million from $23.0 million a year ago, driven by a 59% increase in operating expenses, including an $8.0 million impairment charge. Cash burn accelerated, with cash and investments declining to $243.2 million from $295.1 million at year-end 2025, though the company maintains a cash runway into 2029. No clinical data catalysts were announced, with initial data still expected at a medical conference in 2026.